These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 30642238)
21. Inhibition of PCSK9: is this the way forward for managing residual risk? Chowdhury SR; Rees A Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999 [No Abstract] [Full Text] [Related]
22. INTERIM guidelines for the diagnosis and management of familial hypercholesterolaemia. Sullivan DR; Hamilton-Craig I; van Bockxmeer F; Watts GF; Heart Lung Circ; 2012 Mar; 21(3):159-62. PubMed ID: 22364837 [No Abstract] [Full Text] [Related]
23. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene. Karayan L; Qiu S; Betard C; Dufour R; Roederer G; Minnich A; Davignon J; Genest J Arterioscler Thromb; 1994 Aug; 14(8):1258-63. PubMed ID: 8049186 [TBL] [Abstract][Full Text] [Related]
24. Familial Hypercholesterolaemia in the Era of Genetic Testing. Hughes DP; Viljoen A; Wierzbicki AS Curr Cardiol Rep; 2016 May; 18(5):42. PubMed ID: 27002618 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Raal FJ; Pappu AS; Illingworth DR; Pilcher GJ; Marais AD; Firth JC; Kotze MJ; Heinonen TM; Black DM Atherosclerosis; 2000 Jun; 150(2):421-8. PubMed ID: 10856535 [TBL] [Abstract][Full Text] [Related]
26. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Kajinami K; Yagi K; Higashikata T; Inazu A; Koizumi J; Mabuchi H Am J Cardiol; 1998 Jul; 82(1):113-7. PubMed ID: 9671018 [TBL] [Abstract][Full Text] [Related]
27. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Vohl MC; Szots F; Lelièvre M; Lupien PJ; Bergeron J; Gagné C; Couture P Atherosclerosis; 2002 Feb; 160(2):361-8. PubMed ID: 11849659 [TBL] [Abstract][Full Text] [Related]
31. Familial hypercholesterolaemia in Australia: new insights and developments. Hamilton-Craig IR; Watts GF Med J Aust; 2013 Feb; 198(2):72-3. PubMed ID: 23373481 [No Abstract] [Full Text] [Related]
32. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564 [TBL] [Abstract][Full Text] [Related]
33. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719 [TBL] [Abstract][Full Text] [Related]
34. Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol. Tikkanen MJ; Helve E; Nikkilä EA Eur Heart J; 1987 Aug; 8 Suppl E():97-101. PubMed ID: 3315684 [TBL] [Abstract][Full Text] [Related]
38. The Power to Predict: Does LDLR Mutation Status Determine Statin Responsiveness? Berberich AJ Can J Cardiol; 2022 Mar; 38(3):293-296. PubMed ID: 35032620 [No Abstract] [Full Text] [Related]
39. The effect of pravastatin in relation to low density lipoprotein receptor activity. Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022 [TBL] [Abstract][Full Text] [Related]